BioSpace News Archive

Veracyte, Inc. announced financial results and business progress for the quarter and full year ended December 31, 2017, and provided financial guidance for 2018.

ACADIA Pharmaceuticals Inc. announced its financial results for the fourth quarter and year ended December 31, 2017.

Celgene Corporation has received a Refusal to File letter from the United States Food and Drug Administration regarding its New Drug Application for ozanimod in development for the treatment of patients with relapsing forms of multiple sclerosis.

The technology is the core of a device/digital health platform Uneva Health is developing to reduce the enormous annual costs of inconsistent dosing caused by improper inhaler use while improving patient engagement and compliance.

Sobi intends to continue taking the necessary steps to ensure Orfadin remains accessible to Canadian patients.

Aridis Pharmaceuticals, Inc. today announced that it has created a joint venture with Shenzhen Hepalink Pharmaceutical Group Co., Ltd. (Hepalink), one of China’s leading pharmaceutical companies.

- COMPANIES TO COLLABORATE ON PRODUCT DEVELOPMENT, CLINICAL TRIALS AND REGULATORY ACTIVITIES TO OBTAIN APPROVAL IN U.S. AND E.U. - AGREEMENT COMPLEMENTS AND EXTENDS ABBOTT’S BROAD LINE OF VASCULAR CARE PRODUCTS AND DEMONSTRATES VALUE OF SURMODICS’ PROPRIETARY DRUG-DELIVERY AND WHOLE-PRODUCT SOLUTIONS STRATEGY

Beacon Discovery today announced the formation of a multi-year drug discovery collaboration with Takeda Pharmaceutical Company Limited focused on a number of G-protein coupled receptors (GPCRs) that play an important role in the pathology of gastrointestinal disorders.

EIR Healthcare’s patented modular construction process combined with McKissack’s legacy in construction management space creates a strong duo for advancement in industrial design and building